PDE4A and Alzheimer disease: PDE4-targeted therapy has also shown promising results in other neurological disorders and the same Rolipram, the first blood-brain-barrier permeable PDE4 inhibitor, has been proven to be effective in various animal models of Parkinson’s disease, Alzheimer’s disease, depression and neuropathic pain [159,160,161].